406PResponse assessment of melanoma brain metastases treated by stereotactic radiotherapy or immunotherapy or both: A comparison of RECIST 1.1, RANO and iRANO criteria

ConclusionsWhile the retrospective nature and small sample size for subgroups are major limitations of this study, these data may indicate that the omission of SRT from first-line treatment may compromise outcome. Pseudoprogression is uncommon with immunotherapy alone; pseudoprogression rates were similar after SRT alone or in combination with immunotherapy or other systemic treatment.Legal entity responsible for the studyUniversity Hospital of Zurich.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research

Related Links:

We read with interest the Oncology Scan feature by Minniti et  al regarding the role of immunotherapy in treatment of melanoma brain metastases.1 Although we agree with the facts articulated by authors' review of the 3 articles, we strongly disagree with the premise that the efficacy of multiagent immunotherapy may obviate the need for stereotactic radiosurge ry (SRS) as an important component of optimal care. Although the 57% 6-month local control rate (with a 26% complete response rate) provided by multiagent immune checkpoint inhibitors (ICI) alone is impressive, these numbers still fall well short of the 87% to 91...
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Comment Source Type: research
ConclusionThis case illustrates that a fulminant response to combined checkpoint inhibition is possible after progression after anti-PD-1 monotherapy and a severe irAE.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 22 June 2019Source: Seminars in Cancer BiologyAuthor(s): Fabrizio Fontana, Michela Raimondi, Alessandro Di Domizio, Roberta M. Moretti, Marina Montagnani Marelli, Patrizia LimontaAbstractMelanoma is the most fatal form of skin cancer. Current therapeutic approaches include surgical resection, chemotherapy, targeted therapy and immunotherapy. However, these treatment strategies are associated with development of drug resistance and severe side effects. In recent years, natural compounds have also been extensively studied for their anti-melanoma effects, including tumor growth inhibition, a...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Herein, we report an atypical clinicopathological presentation of amelanotic melanoma first diagnosed in the oral cavity of a 68-year-old man. The tumor was immunopositive for HMB45 and S-100, and weakly positive to Melan A. PET (positron emission tomography) and CT (computed tomography) scans demonstrated widespread organ and bone metastases, obviating surgical intervention. Standard immunotherapy was instituted with ipilimumab and nivolumab. At 3-weeks, near resolution of the oral lesion was evident and repeat imaging showed resolution of the left lung lesions and marked reductions in size of other affected sites.
Source: Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics - Category: ENT & OMF Authors: Tags: #54 Source Type: research
Conclusions: In this retrospective study of patients with advanced melanoma treated with PD-1 antibodies, tumor response by standard PERCIST was significantly correlated with OS. Modifications of the PERCIST criteria to account for inflammatory lesions did not substantially improve the prognostic value of tumor response on FDG PET. While these results are promising for the use of FDG PET for monitoring immunotherapy, further studies are warranted to understand the impact of the type of immunotherapy and the timing of the FDG PET scans on response assessment. Table1PERCISTCMRPMRSMDPMDtotalimPERCISTCMR1300013PMR02301235SMD02...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Source Type: research
Conclusions: In combinational immunotherapy more than 60% of the pts develop AE. FDG avidity of the affected organs has the potential to noninvasively monitor inflammatory reaction and therefore might prove helpful in 28% of these patients to alter clinical decisions for therapy continuation.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Source Type: research
Conclusions: Post-operative F-18 FDG PET/CT surveillance is valuable for monitoring recurrence of cutaneous melanoma with high sensitivity and negative predictive value, and can help guide clinical managements.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Posters Source Type: research
Conclusions: In patients with advanced melanoma, the immune response to anti-PD-1 therapy appears to occur early, with evidence of T cell reinvigoration in the blood at 1 week post-therapy; an associated flare response on FDG PET/CT imaging at 1 week post-therapy is predictive of a complete response to immunotherapy.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Sarcoma/ Melanoma Posters Source Type: research
Conclusion: We demonstrated that 89Zr-Df-YY146 and IR700-YY146 are a promising theranostic pair with the former revealing CD146 expression in melanoma as a PET probe and the latter specifically treating CD146-positive melanoma as an effective PIT agent.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Center for Molecular Imaging Innovation & amp; Translation (CMIIT) YIA Symposium Source Type: research
The National Cancer Institute has opened a clinical trial using mesothelioma patients and their family members to explore predisposition to the cancer and potential solutions to negating it. The trial is a follow up to an earlier study of a genetic mutation that creates susceptibility to various cancers but a longer-than-normal survival with platinum-based chemotherapy treatment. “This is an important, long-term study that could have implications not only for a patient, but for family members, too,” Dr. Raffit Hassan, NCI senior investigator told The Mesothelioma Center at Asbestos.com. “Progress can be m...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Brain | Cancer & Oncology | Immunotherapy | Legislation | Melanoma | Neurology | PET Scan | Skin Cancer | Study